Irinotecan and Anlotinib for Epithelioid Sarcoma

Peking University People's Hospital

Overview

Epithelioid sarcoma is a rare soft tissue sarcoma characterized by SMARCB1/INI1 deficiency. Much attention has been paid to the selective EZH2 inhibitor tazemetostat, where other systemic treatments are generally ignored. To explore alternative treatment options, we studied the effects of irinotecan-based chemotherapy in a series of epithelioid sarcoma patients.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Conditions

Objective Response Overall Survival

Interventions

VIA combination treatmentDRUG

a 90-minute intravenous infusion of irinotecan at a dose of 50 mg/m2/d for 5 days every 3 weeks, vincristine given at a dose of 1.4 mg/m2 (maximum 2 mg) on days 1 and 8, and oral administration of Anlotinib once daily on days 1-14 within a 21-day cycle.

Eligibility

Sex: ALLMin age: 3 Years

Medical Language ↔ Plain English

Inclusion Criteria: * (1) Grade 2 or 3 ES confirmed histologically using the American Joint Committee on Cancer (AJCC) system ; * (2) patients presented with measurable lesions using the Response Evaluation Criteria In Solid Tumors (RECIST1.1) and were not amenable to surgical resection or radiotherapy; * (3) primary or secondary metastatic disease; * (4) received more than two courses of the VIA regimen; * (5) no concurrent treatment was given while on the VIA regimen; * (6) follow-up information and evaluation after chemotherapy were available. Exclusion Criteria: * less than 4 cycles of treatment; * medical records were not complete.

Locations (1)

Peking University People's Hospital

Beijing, China

Outcomes

Primary Outcomes

Objective Response Rate

Based on RECIST1.1 criteria, clinical evaluation was done once every 6 weeks

Time frame: 12 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.